Premethylenomycin C lactone is a natural product with potent antibiotic activity, effective in vitro against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Discovery The compound was identified unintentionally during investigations of the methylenomycin biosynthetic gene cluster in Streptomyces coelicolor, a bacterium found in soil. Genetic blockade of a specific enzymatic step by deletion of the mmyE gene led to the accumulation and isolation of previously uncharacterized intermediates, including premethylenomycin C and its lactone derivative. In the biosynthetic pathway that produces methylenomycin A, premethylenomycin C lactone is an early intermediate. Hydrolysis of the lactone ring followed by dehydration yields methylenomycin C, which is subsequently oxidized to form the epoxide methylenomycin A.
Bioactivity Compared with methylenomycin A and methylenomycin C, premethylenomycin C and its lactone precursor exhibit antimicrobial activity one to two orders of magnitude greater against a range of Gram-positive bacteria, including antibiotic-resistant isolates of Staphylococcus aureus and Enterococcus faecium. They also do not have the α-methylene-γ-butyrolactone pharmacophore of methylenomycin A and C, implying they have a different mode of action. These properties highlight the compounds in this metabolic series as potential lead structures for developing new antibiotics to combat antimicrobial resistance.
Chemistry Beyond its natural production, premethylenomycin C lactone can be prepared synthetically via a diastereoselective, phosphine-mediated (3 + 2) cycloaddition reaction, providing a route for larger‑scale preparation and structure–activity relationship studies.
References
Further reading



